IL157465A0 - Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders - Google Patents

Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Info

Publication number
IL157465A0
IL157465A0 IL15746502A IL15746502A IL157465A0 IL 157465 A0 IL157465 A0 IL 157465A0 IL 15746502 A IL15746502 A IL 15746502A IL 15746502 A IL15746502 A IL 15746502A IL 157465 A0 IL157465 A0 IL 157465A0
Authority
IL
Israel
Prior art keywords
estrogen
agonists
vitamin
treatment
combination
Prior art date
Application number
IL15746502A
Other languages
English (en)
Original Assignee
Pfizer Products Inc Pfizer Pro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc Pfizer Pro filed Critical Pfizer Products Inc Pfizer Pro
Publication of IL157465A0 publication Critical patent/IL157465A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL15746502A 2001-03-01 2002-02-20 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders IL157465A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27256601P 2001-03-01 2001-03-01
PCT/IB2002/000515 WO2002069948A1 (en) 2001-03-01 2002-02-20 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
IL157465A0 true IL157465A0 (en) 2004-03-28

Family

ID=23040351

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15746502A IL157465A0 (en) 2001-03-01 2002-02-20 Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders

Country Status (33)

Country Link
US (2) US20020193360A1 (xx)
EP (1) EP1363606A1 (xx)
JP (1) JP2004527500A (xx)
KR (1) KR20030076717A (xx)
CN (1) CN1494422A (xx)
AP (1) AP2002002465A0 (xx)
AR (1) AR033425A1 (xx)
BG (1) BG108131A (xx)
BR (1) BR0207802A (xx)
CA (1) CA2439581A1 (xx)
CR (1) CR7059A (xx)
CZ (1) CZ20032338A3 (xx)
DO (1) DOP2002000345A (xx)
EA (1) EA200300854A1 (xx)
EC (1) ECSP034759A (xx)
EE (1) EE200300422A (xx)
GT (1) GT200200039A (xx)
HU (1) HUP0303448A3 (xx)
IL (1) IL157465A0 (xx)
IS (1) IS6905A (xx)
MA (1) MA26999A1 (xx)
MX (1) MXPA03007834A (xx)
NO (1) NO20033821L (xx)
NZ (1) NZ527397A (xx)
OA (1) OA12554A (xx)
PA (1) PA8540701A1 (xx)
PE (1) PE20020927A1 (xx)
PL (1) PL364081A1 (xx)
SK (1) SK10752003A3 (xx)
TN (1) TNSN02018A1 (xx)
UY (1) UY27188A1 (xx)
WO (1) WO2002069948A1 (xx)
ZA (1) ZA200306193B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20080004332A1 (en) * 2002-03-07 2008-01-03 Alkon Daniel L Methods for alzheimer's disease treatment and cognitive enhancement
US20050065205A1 (en) * 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
WO2005000806A2 (en) 2003-06-10 2005-01-06 Georgetown University Ligands for nicotinic acetylcholine receptors, and methods of making and using them
TW200538181A (en) 2004-05-18 2005-12-01 Brni Neurosciences Inst Treatment of depressive disorders
US8510055B2 (en) 2005-08-03 2013-08-13 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
WO2007019312A2 (en) * 2005-08-03 2007-02-15 The Johns Hopkins University Methods for characterizing and treating cognitive impairment in aging and disease
CA2935516A1 (en) * 2006-05-22 2007-12-06 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
WO2008046135A1 (en) 2006-10-16 2008-04-24 Bionomics Limited Novel anxiolytic compounds
AU2013202426B2 (en) * 2006-10-16 2015-08-06 Bionomics Limited Novel anxiolytic compounds
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
KR20090119894A (ko) 2007-02-09 2009-11-20 블랜체트 록펠러 뉴로사이언시즈 인스티튜트 두부 외상-유도된 기억 장애 및 뇌 손상에 대한 브리오스타틴, 브리오로그 및 기타 관련 물질의 치료학적 효과
CA2709774C (en) * 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
US20100010221A1 (en) * 2008-07-10 2010-01-14 Revital Lifshitz-Liron Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
US10206921B2 (en) * 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
US8178537B2 (en) * 2009-06-22 2012-05-15 Teva Pharmaceutical Industries Ltd. Solid state forms of varenicline salts and processes for preparation thereof
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
CN103502219A (zh) 2011-03-02 2014-01-08 生态学有限公司 作为治疗剂的新型小分子
EP2680842A4 (en) * 2011-03-02 2014-10-29 Bionomics Ltd METHOD FOR THE TREATMENT OF A DISEASE OR A SENSE OF THE CENTRAL NERVOUS SYSTEM
JP6055817B2 (ja) 2011-05-12 2016-12-27 バイオノミックス リミテッド ナフチリジンの調製方法
CN112409363B (zh) 2013-12-20 2023-11-14 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂䓬衍生物、组合物和方法
MX2017015752A (es) 2015-06-19 2018-04-13 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar deterioro cognitivo.
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
MX2020013927A (es) 2018-06-19 2021-03-02 Agenebio Inc Derivados de benzodiazepina, composiciones y metodos para tratar el deterioro cognitivo.
CN116008442B (zh) * 2023-03-27 2023-06-30 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的合成中间体的杂质检测方法
CN116077459B (zh) * 2023-04-10 2023-07-07 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂的胶囊剂及其制备方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001514181A (ja) * 1997-08-25 2001-09-11 ニューロゲン コーポレイション Ｇａｂａ脳レセプタリガンドとしての置換４−オキソ−ナフチリジン−３−カルボキサミド
US6448246B1 (en) * 1999-05-25 2002-09-10 Neurogen Corporation Substituted 4H-1,4-benzothiazine-2-carboxamide: GABA brain receptor ligands

Also Published As

Publication number Publication date
IS6905A (is) 2003-08-07
AR033425A1 (es) 2003-12-17
CA2439581A1 (en) 2002-09-12
ECSP034759A (es) 2003-10-28
US20020193360A1 (en) 2002-12-19
PL364081A1 (en) 2004-12-13
EA200300854A1 (ru) 2004-02-26
ZA200306193B (en) 2004-08-11
NZ527397A (en) 2005-05-27
TNSN02018A1 (fr) 2005-12-23
SK10752003A3 (sk) 2004-08-03
OA12554A (en) 2006-06-07
BR0207802A (pt) 2004-03-09
MXPA03007834A (es) 2003-12-08
CZ20032338A3 (cs) 2004-08-18
JP2004527500A (ja) 2004-09-09
DOP2002000345A (es) 2002-12-15
HUP0303448A2 (hu) 2004-01-28
CR7059A (es) 2004-03-10
HUP0303448A3 (en) 2005-05-30
GT200200039A (es) 2002-11-21
UY27188A1 (es) 2002-10-31
US20040082555A1 (en) 2004-04-29
AP2002002465A0 (en) 2002-06-30
NO20033821L (no) 2003-09-10
PE20020927A1 (es) 2002-10-30
NO20033821D0 (no) 2003-08-28
PA8540701A1 (es) 2002-09-30
EE200300422A (et) 2004-02-16
BG108131A (en) 2004-09-30
KR20030076717A (ko) 2003-09-26
WO2002069948A1 (en) 2002-09-12
EP1363606A1 (en) 2003-11-26
MA26999A1 (fr) 2004-12-20
CN1494422A (zh) 2004-05-05

Similar Documents

Publication Publication Date Title
HUP0303448A3 (en) Use of gabaa inverse agonists in combination with nicotine receptor partial agonists, estrogen, selective estrogen modulators, or vitamin e for the treatment of cognitive disorders
HK1152243A1 (en) Vegf for use in the treatment of central nervous system disorders vegf
IL158745A0 (en) Heating member for combination heating and chilling apparatus, and methods
PL373626A1 (en) Treatment for central nervous system disorders
IL155225A0 (en) Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
GB2371557B (en) Method for the preparation of hydrogenated hydrocarbons
IL172043A0 (en) Treating bone-related disorders with selective androgen receptor modulators
MXPA03008178A (es) Composcion, aparato y metodo para el rejuvenecimiento de la piel.
HK1039752B (zh) 治療細胞增生失調的呼吸道腸道病毒
AU8821301A (en) Selective androgen receptor modulators and methods for their identification, design and use
PL362030A1 (en) Ep4 receptor selective agonists in the treatment of osteoporosis
PL377296A1 (pl) Pochodne 1,5-diarylo-pirolo-3-karboksyamidu oraz ich zastosowanie jako modulatorów receptora kannabinoidowego
HK1068336A1 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use as antitumor agents
HK1057864A1 (en) Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders.
ZA200108797B (en) Process for the preparation of non-steroidal glucocorticoid receptor modulators.
IL175303A0 (en) Oral formulations for 5-ht-receptor agonists, uses and methods of treatment employing the same
EP1409015A4 (en) METHODS OF TREATING OR PREVENTING SKIN DISORDERS USING CD2 BINDING AGENTS
ZA200305230B (en) Methods to identify compounds useful for the treament of proliferative and differentiative disorders.
MXPA03006478A (es) Derivados de cromano, procedimiento para su preparacion y su uso como agentes antitumorales.
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
ZA200205098B (en) Dihydrobenzopyrans, dihydrobenzothiopyrans, and tetrahydroquinolines for the treatment of cox-2-mediated disorders.
AU2003263301A8 (en) Alternative processes for the preparation of d- (+) -morphine, and d- (+) - morphine tartrate
PL370842A1 (en) Selective dopamin d3 receptor agonists for the treatment of sexual dysfunction
TW200637545A (en) Novel uses for estrogen beta agonists
MXPA03006249A (es) Derivados de 2-arilimino-2,3-dihidrotiazoles, sus procesos de preparacion y su uso terapeutico.